Published in Arthritis Res Ther on January 01, 2007
Treatment and prevention of bone complications from prostate cancer. Bone (2010) 1.60
Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol (2010) 1.49
Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res (2011) 1.23
Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther (2008) 1.05
Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett (2009) 1.04
Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. J Orthop Res (2008) 1.02
Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One (2010) 1.01
Emerging treatments for postmenopausal osteoporosis - focus on denosumab. Clin Interv Aging (2009) 0.98
Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis. J Biol Chem (2011) 0.97
Effects of antiresorptive agents on osteomyelitis: novel insights into the pathogenesis of osteonecrosis of the jaw. Ann N Y Acad Sci (2010) 0.89
Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options. Can Urol Assoc J (2010) 0.89
A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease. Expert Opin Biol Ther (2009) 0.87
Novel agents in the management of castration resistant prostate cancer. J Carcinog (2014) 0.87
Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer (2010) 0.85
Cancer pain physiology. Br J Pain (2014) 0.84
Painful boney metastases. Korean J Pain (2013) 0.83
High affinity humanized antibodies without making hybridomas; immunization paired with mammalian cell display and in vitro somatic hypermutation. PLoS One (2012) 0.83
Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. Inflammopharmacology (2013) 0.82
The emerging field of osteoimmunology. Immunol Res (2009) 0.81
Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches. Hippokratia (2010) 0.80
Targeting dendritic cell function during systemic autoimmunity to restore tolerance. Int J Mol Sci (2014) 0.80
Osteocytic signalling pathways as therapeutic targets for bone fragility. Nat Rev Endocrinol (2016) 0.80
Effect of bisphosphonates on orthodontic tooth movement-an update. J Clin Diagn Res (2015) 0.78
Prostate cancer and bone: the elective affinities. Biomed Res Int (2014) 0.78
Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow. Clin Oral Investig (2015) 0.75
Bone health in nonmetastatic prostate cancer: what's the big deal? Curr Oncol (2010) 0.75
Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim. Biomed Imaging Interv J (2008) 0.75
Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. Anticancer Res (2012) 0.75
Current and emerging therapies for the treatment of osteoporosis. J Exp Pharmacol (2010) 0.75
Local application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit model. PeerJ (2017) 0.75
Osteoclast differentiation and activation. Nature (2003) 18.59
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med (2006) 7.46
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem (1997) 4.61
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res (2004) 3.17
Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine (1995) 2.34
Human antibodies from transgenic animals. Nat Biotechnol (2005) 2.04
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol (2005) 2.03
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res (2006) 1.99
RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res (2004) 1.83
Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol (2003) 1.77
TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med (1999) 1.67
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer (2003) 1.65
The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res (2001) 1.57
OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology (2001) 1.41
Osteonecrosis of the jaw: more research needed. J Bone Miner Res (2006) 1.36
Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone (2006) 1.26
Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods (1999) 1.23
Fully human therapeutic monoclonal antibodies. J Immunother (2005) 1.20
Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum (1996) 1.19
In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res (2002) 1.17
Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J Orthop Res (2003) 1.10
Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis (1989) 0.96
Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum (2005) 0.95
Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin Immunol (2003) 0.91
Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role. Arthritis Res Ther (2006) 0.90
The long and the short of bone therapy. N Engl J Med (2006) 0.86
Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol (1994) 0.86
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 2.80
National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol (2007) 2.29
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol (2004) 2.07
Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum (2004) 1.94
Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol (2006) 1.70
Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography. Arthritis Rheum (2007) 1.68
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum (2009) 1.54
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum (2007) 1.44
MRI and quantification of draining lymph node function in inflammatory arthritis. Ann N Y Acad Sci (2007) 1.41
Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med (2006) 1.29
Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep (2006) 1.29
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med (2014) 1.23
Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res (2012) 1.19
CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther (2010) 1.17
CD23(+)/CD21(hi) B-cell translocation and ipsilateral lymph node collapse is associated with asymmetric arthritic flare in TNF-Tg mice. Arthritis Res Ther (2011) 1.15
Elucidating bone marrow edema and myelopoiesis in murine arthritis using contrast-enhanced magnetic resonance imaging. Arthritis Rheum (2008) 1.14
RANKL induces heterogeneous DC-STAMP(lo) and DC-STAMP(hi) osteoclast precursors of which the DC-STAMP(lo) precursors are the master fusogens. J Cell Physiol (2010) 1.13
Treatment update on spondyloarthropathy. From NSAIDs and DMARDs to anti-TNF-alpha agents. Postgrad Med (2004) 1.08
Consensus guidelines for the management of plaque psoriasis. Arch Dermatol (2012) 1.06
Efficacy of B cell depletion therapy for murine joint arthritis flare is associated with increased lymphatic flow. Arthritis Rheum (2013) 1.05
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther (2011) 1.00
Autoimmunity and bone. Ann N Y Acad Sci (2006) 0.98
An 11-color flow cytometric assay for identifying, phenotyping, and assessing endocytic ability of peripheral blood dendritic cell subsets in a single platform. J Immunol Methods (2008) 0.98
Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol (2004) 0.95
In vivo quantification of lymph viscosity and pressure in lymphatic vessels and draining lymph nodes of arthritic joints in mice. J Physiol (2014) 0.93
Outcome measures in psoriatic arthritis. J Rheumatol (2005) 0.88
Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review. J Rheumatol (2008) 0.87
The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol (2009) 0.85
Mediation of nonerosive arthritis in a mouse model of lupus by interferon-alpha-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. Arthritis Rheum (2010) 0.85
Validation of power Doppler versus contrast-enhanced magnetic resonance imaging quantification of joint inflammation in murine inflammatory arthritis. J Bone Miner Res (2015) 0.84
Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol (2010) 0.84
Treatment update on spondyloarthropathy. Curr Opin Rheumatol (2005) 0.84
Measuring intranodal pressure and lymph viscosity to elucidate mechanisms of arthritic flare and therapeutic outcomes. Ann N Y Acad Sci (2011) 0.82
Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther (2010) 0.82
Altered bone biology in psoriatic arthritis. Curr Rheumatol Rep (2012) 0.80
The role of bone marrow edema and lymphangiogenesis in inflammatory-erosive arthritis. Adv Exp Med Biol (2010) 0.79
Etanercept in psoriatic arthritis. Expert Opin Biol Ther (2003) 0.79
2007 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). J Rheumatol (2008) 0.78
Troponin T3 expression in skeletal and smooth muscle is required for growth and postnatal survival: characterization of Tnnt3(tm2a(KOMP)Wtsi) mice. Genesis (2013) 0.78
Mechanisms of erosion in rheumatoid arthritis. J Rheumatol (2004) 0.78
Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol (2010) 0.78
Mechanistic insights from animal models of psoriasis and psoriatic arthritis. Curr Rheumatol Rep (2013) 0.77
Altered bone remodeling in psoriatic arthritis. Curr Rheumatol Rep (2008) 0.77
Targeting the interleukin-23/17 axis in axial spondyloarthritis. Curr Opin Rheumatol (2016) 0.77
Proceedings of the 5th annual perspectives in rheumatic diseases. Semin Arthritis Rheum (2013) 0.76
Characterization of DC-STAMP+ Cells in Human Bone Marrow. J Bone Marrow Res (2013) 0.76
Transient decrease in human peripheral blood myeloid dendritic cells following influenza vaccination correlates with induction of serum antibody. Immunol Invest (2014) 0.75
Comparison of methotrexate and cyclosporine therapy in psoriasis. Curr Rheumatol Rep (2004) 0.75
Efalizumab therapy in plaque psoriasis. Curr Rheumatol Rep (2004) 0.75
Treatment of psoriasis with intramuscular alefacept. Curr Rheumatol Rep (2004) 0.75
Etanercept monotherapy in psoriasis. Curr Rheumatol Rep (2004) 0.75
Biomarkers of radiographic progression in psoriatic arthritis: a report from the GRAPPA 2011 annual meeting. J Rheumatol (2012) 0.75
GRAPPA Trainees Symposium 2011: a report from the GRAPPA 2011 annual meeting. J Rheumatol (2012) 0.75
Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis. Curr Opin Rheumatol (2015) 0.75
The comparative effectiveness of methotrexate and anti-tumor necrosis factor therapy in psoriatic arthritis. Curr Rheumatol Rep (2008) 0.75
Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. Expert Opin Biol Ther (2014) 0.75
The path forward to biomarker discovery in psoriatic disease: a report from the GRAPPA 2010 annual meeting. J Rheumatol (2012) 0.75
Summary of the International Federation of Psoriasis Associations (IFPA) meeting: a report from the GRAPPA 2009 annual meeting. J Rheumatol (2011) 0.75
GRAPPA Trainees Symposium 2012: a report from the GRAPPA 2012 annual meeting. J Rheumatol (2013) 0.75
GRAPPA Trainees Symposium 2009: a report from the GRAPPA 2009 annual meeting. J Rheumatol (2011) 0.75
Pseudoxanthoma elasticum masquerading as Sjögren's syndrome. J Clin Rheumatol (2002) 0.75